Clinuvel Pharmaceuticals Ltd
OTC:CLVLY

Watchlist Manager
Clinuvel Pharmaceuticals Ltd Logo
Clinuvel Pharmaceuticals Ltd
OTC:CLVLY
Watchlist
Price: 8.275 USD 1.53%
Market Cap: 426.9m USD
Section:
 

Relative Value

The Relative Value of one CLVLY stock under the Base Case scenario is 10.596 USD. Compared to the current market price of 8.275 USD, Clinuvel Pharmaceuticals Ltd is Undervalued by 22%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CLVLY Relative Value
Base Case
10.596 USD
Undervaluation 22%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

6.9
P/S
P/S
Price to Sales
6.9
vs History
77
vs Industry
55
Median 3Y
8.2
Median 5Y
11.3
Industry
7.9
Forward
6.2
More Details
18
P/E
P/E
Price to Earnings
18
vs History
79
vs Industry
9
Median 3Y
23.1
Median 5Y
32.4
Industry
24
Forward
16.5
More Details
15.8
P/OCF
P/OCF
Price to OCF
15.8
vs History
88
vs Industry
8
Median 3Y
20.6
Median 5Y
23.8
Industry
21.6
More Details
16
P/FCFE
P/FCFE
Price to FCFE
16
vs History
88
vs Industry
8
Median 3Y
22.5
Median 5Y
24.7
Industry
23.7
More Details
2.7
P/B
P/B
Price to Book Value
2.7
vs History
82
vs Industry
33
Median 3Y
3.9
Median 5Y
6
Industry
3.4
More Details
4.5
EV/S
EV/S
Enterprise Value to Sales
4.5
vs History
79
vs Industry
55
Median 3Y
6.3
Median 5Y
9.5
Industry
8.3
Forward
4.1
More Details
4.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.6
vs History
79
vs Industry
59
Median 3Y
6
Median 5Y
9.7
Industry
10.3
More Details
9.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
9.3
vs History
76
vs Industry
13
Median 3Y
10.7
Median 5Y
17.6
Industry
6.7
Forward
9
More Details
9.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
9.3
vs History
76
vs Industry
11
Median 3Y
10.7
Median 5Y
17.6
Industry
7.2
Forward
9.6
More Details
10.4
EV/OCF
EV/OCF
Enterprise Value to OCF
10.4
vs History
88
vs Industry
11
Median 3Y
15.5
Median 5Y
19.5
Industry
8.2
More Details
10.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
10.5
vs History
88
vs Industry
8
Median 3Y
17.2
Median 5Y
19.7
Industry
6.7
More Details
11.3
EV/IC
EV/IC
Enterprise Value to IC
11.3
vs History
85
vs Industry
17
Median 3Y
17
Median 5Y
32.8
Industry
5.7
More Details

Multiples Across Competitors

CLVLY Competitors Multiples
Clinuvel Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Clinuvel Pharmaceuticals Ltd
OTC:CLVLY
651.1m USD 6.9 18 9.3 9.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 067 817 -161 919.3 -196 621.7 -194 378
US
Abbvie Inc
NYSE:ABBV
394.3B USD 6.6 167.9 16.3 23.1
US
Amgen Inc
NASDAQ:AMGN
172.8B USD 4.8 24.7 17.9 17.9
US
Gilead Sciences Inc
NASDAQ:GILD
150.5B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.3B USD 9.6 30.6 22.4 23.4
US
Epizyme Inc
F:EPE
94.1B EUR 2 067.9 -527.7 -574.6 -559.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
74.1B USD 5.2 16.2 15.3 17.4
AU
CSL Ltd
ASX:CSL
88B AUD 3.7 19.4 13.1 16.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
56.7B USD 17.7 1 300.9 171.3 207.7
NL
argenx SE
XBRU:ARGX
47.3B EUR 15.3 36 62.3 64
P/E Multiple
Earnings Growth PEG
AU
Clinuvel Pharmaceuticals Ltd
OTC:CLVLY
Average P/E: 181.4
18
17%
1.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 919.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
167.9
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.7
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.6
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
9%
1.8
AU
CSL Ltd
ASX:CSL
19.4
11%
1.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 300.9
N/A N/A
NL
argenx SE
XBRU:ARGX
36
40%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Clinuvel Pharmaceuticals Ltd
OTC:CLVLY
Average EV/EBITDA: 37.8
9.3
17%
0.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 621.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.9
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.4
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.3
11%
1.4
AU
CSL Ltd
ASX:CSL
13.1
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
171.3
N/A N/A
NL
argenx SE
XBRU:ARGX
62.3
807%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Clinuvel Pharmaceuticals Ltd
OTC:CLVLY
Average EV/EBIT: 43.5
9.3
13%
0.7
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 378 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.9
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.4
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
13%
1.3
AU
CSL Ltd
ASX:CSL
16.3
11%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
207.7
N/A N/A
NL
argenx SE
XBRU:ARGX
64
N/A N/A

See Also

Summary
CLVLY intrinsic value, competitors valuation, and company profile.
DCF Valuation
CLVLY stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CLVLY stock valuation using valuation multiples.
Wall Street Estimates
CLVLY price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CLVLY stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 301,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.